news
EMA releases results from February meeting, recommending two medicines
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
List view / Grid view
Ovarian Cancer
news
FDA accepts Zejula sNDA application as a maintenance treatment for ovarian cancer
The developers of Zejula (niraparib) have announced the FDA will assess the sNDA application under the Real-Time Oncology Review (RTOR) pilot programme.
article
The biggest pharma merger and acquisition deals of 2019
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
news
NICE recommends olaparib tablets for platinum-sensitive cancer patients
NICE has recommended olaparib tablets (Lynparza, AstraZeneca) for adults with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer with a BRCA1 or BRCA2 mutation.
news
NICE approves new tablet formulation for olaparib drug
The UK NICE has extended its approval for olaparib, updating its formulation from eight capsules twice a day to two tablets twice daily.
news
Lynparza has been approved for BRCA-mutated advanced ovarian cancer
BRCA-mutated advanced ovarian cancer treatment has been approved by the European Commission.
news
Pivotal phase III trial launched in recurrent ovarian cancer
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer...
news
Losartan could improve ovarian cancer treatment
Researchers have found that losartan could be beneficial for those undergoing cancer treatment as it may enhance its effectiveness...
news
Ovarian cancer risks may be lowered with aspirin
A Harvard Chan School of Public Health study showed aspirin specifically in low doses could lower the risk of ovarian cancer...
news
Scientists identify cause of resistance to breast and ovarian cancer drug
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors...
news
Hemp shows potential for treating ovarian cancer
Researchers demonstrate hemp's ability to slow cancer growth and uncover mechanism for its cancer-fighting ability...
news
Ponatinib is found to be effective against SCCOHT
Ponatinib is effective against SCCOHT, a type of ovarian cancer that mostly strikes young women and girls as young as 14 months...
news
FDA approves lynparza for breast cancer with BRCA gene mutation
The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...
news
Merrimack initiates Phase 1 study of MM-310 in solid tumours
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
news
Lynparza Phase III data demonstrates progression-free survival in ovarian cancer
17 March 2017 | By Niamh Marriott, Junior Editor
AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95%…
